Elan Drug Technologies, a business unit of Elan
Corporation, plc has announced plans to officially launch its
Manufacturing Services business at the CPhI world event in Paris.

“We are very excited to be launching our Manufacturing
Services business at this world wide event where up to 25,000 pharmaceutical peers
meet. For over forty years, Elan Drug Technologies has been a leading provider
of drug delivery technologies and dosage form development for the pharmaceutical
market,” said Shane Cooke, Executive Vice President and Head of Elan Drug
Technologies. “We look forward to expanding our services in commercial
scale-up and manufacturing, where we can offer a broad range of manufacturing solutions
for our clients from our facilities in Europe and the US.” Elan’s
Manufacturing Services offers a significant advantage in outsourcing, including
a broad range of services and expertise integrated to one company that is based
in the US and Europe. Building on its over forty years of experience in
drug delivery, Elan provides pharmaceutical clients with process design and
development expertise, process improvements as well as improved production
methods in scale-up and commercial manufacturing. Elan’s outstanding quality compliance,
together with its excellent track record in product optimisation, have made EDT
the supplier of choice for an impressive number of pharmaceutical companies
including seven of the world’s leading pharmaceutical companies.

To support the launch of its Manufacturing Services
business, Philip Pratten joins the Elan team as Vice President, Manufacturing
Services Operations, having worked in Catalent Pharma Solutions and previously with
Cardinal Health, GlaxoWellcome and the Wellcome Foundation. He has almost
thirty years of broad based experience in the pharma industry and graduated
with a degree in Biophysical Science from North East London Polytechnic (now University of East London).